Figure 1
Flowchart of this study. Patients of Brugada syndrome (BrS) cohort-I were assigned to groups of loss-of-function (LOF) SCN5A mutation carriers (N = 45), non-loss-of-function SCN5A variation carriers (N = 15), and SCN5A-mutation negative patients (SCN5A(−), N = 355) by in silico curation, PubMed search and functional evaluation using patch clamp. Numbers of unique variations (n) and patients (Pt) are shown where a duplication was identified. Brugada syndrome cohort-II consists of independent Brugada syndrome probands carrying no SCN5A rare variations.

Flowchart of this study. Patients of Brugada syndrome (BrS) cohort-I were assigned to groups of loss-of-function (LOF) SCN5A mutation carriers (N = 45), non-loss-of-function SCN5A variation carriers (N = 15), and SCN5A-mutation negative patients (SCN5A(−), N = 355) by in silico curation, PubMed search and functional evaluation using patch clamp. Numbers of unique variations (n) and patients (Pt) are shown where a duplication was identified. Brugada syndrome cohort-II consists of independent Brugada syndrome probands carrying no SCN5A rare variations.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close